Silence Therapeutics (SLN) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$615,000.00

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

$528,000.00

Gross margin

85.85%

Net income (trailing twelve months)

−$60.0M

Net income (quarter)

−$12.3M

Net income growth (year over year)

+55.15%

Net margin

−9748.46%

Return on equity

−90.41%

EPS (trailing twelve months)

−$1.29

Book value per share

$0.81

P/E (trailing twelve months)

—

Price to book

14.05

Debt to assets

63.85%

Payout ratio

—

Dividend yield

—

Company profile

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

• Is Silence Therapeutics (SLN) profitable?

  No. Silence Therapeutics reported a net loss of $60.0M over the trailing twelve months.

• How much revenue does Silence Therapeutics (SLN) make?

  Silence Therapeutics generated $615,000.00 in revenue over the trailing twelve months.

• How do I buy stock in Silence Therapeutics (SLN)?

  SLN trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.